Skip to main content

Table 1 Baseline characteristics of all patients and patients with/ without an increase in LDL-C after pemafibrate

From: Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Characteristic Total Increased LDL-C group
(group I)a
No LDL-C increase group
(group NI)b
P*
Cases no. (%) 51(100) 25 (49) 26 (51)  
Cases of LDL-C increase, no. (%) 35 (69) 25 (100) 10 (38)  
% increase in LDL-C, median (IQR) 5.3 (−3.8–19.1) 19.1 (13.3–56.3) − 3.7 (−13.0–1.2)  
Males, no. (%) 28 (55) 17 (68) 11 (42) 0.0653
Age, mean (SD), years 62.2 (12.9) 60.7 (13.2) 63.7 (12.7) 0.4168
BMI, mean (SD), kg/m2 26.6 (3.7) 27.1 (4.0) 26.1 (3.4) 0.3496
HbA1c, mean (SD), % 7.4 (1.4) 7.2 (1.3) 7.5 (1.5) 0.5568
eGFR, mean (SD), mL /min/1.73 m2 71.9 (22.3) 74.8 (23.4) 69.2 (21.3) 0.3732
Complications
 Hypertension, no. (%) 30 (59) 14 (56) 16 (62) 0.6879
 CVD/stroke, no. (%) 9 (18) 6 (24) 3 (12) 0.2432
Treatment for diabetes
 OHA, no. (%) 36 (71) 16 (64) 20 (77) 0.4685
 Insulin + OHA, no. (%) 4 (8) 3 (12) 1 (4)
  1. a% increase in LDL-C > 5.3%; b% increase in LDL-C < 5.3%. P < 0.05 was considered statistically significant (χ2 test or t-test). *Statistical analysis between increased LDL-C and no LDL-C increase groups using the χ2 test or the t-test. BMI Body mass index, HbA1c Glycated hemoglobin, eGFR Estimated glomerular filtration rate, LDL-C Low density lipoprotein cholesterol, IQR Inter-quartile range, OHA ORAL hypoglycemic agents.